Warnings against candesartan in pregnancy are not implemented in physicians' practice.
Borthen
Camilla
C
Oglaend
Bjørn
B
Eggebøe
Torbjørn
T
Ellingsen
Christian Lycke
CL
Schjøtt
Jan
J
D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004359:Drug Therapy, Combination; D005260:Female; D005313:Fetal Death / Q000139:chemically induced*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D016104:Oligohydramnios / Q000139:chemically induced*; D010818:Practice Patterns, Physicians'; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use*
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D006852:Hydrochlorothiazide; C081643:candesartan